Telangana Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu awarding the Genome Valley Excellence Award, an integral a part of BioAsia, to Edward Netter, Professor of Most cancers Gene Remedy, Perelman Faculty of Medication, College of Pennsylvania, USA, in Hyderabad, Tuesday, February 17, 2026. Picture credit score: Nagara Gopal
India has the potential to maneuver up the pharmaceutical worth chain from its current dominant place because the world’s main generic drug maker to a number one participant in innovation, particularly drug discovery, trade leaders mentioned on Tuesday (February 17, 2026), if supported by enough financing.
Other than options to handle financing challenges for India to maneuver from a volume-based to a value-based technique, different catalysts to speed up the method embrace regulatory assist, trade leaders attending the CEO Convention held at BioAsia on Tuesday (February 17, 2026) sought to emphasise. The theme of the conclave was “The Way forward for Pharma and Biotechnology – Progress, Headwinds, and Alternatives.”
Contemplating the sources required and the restrictions of listed firms, there’s a must encourage different funding strategies by way of the affect of elevated R&D bills on income, mentioned GV Prasad, co-chairman and managing director, Reddy’s Laboratories.
“There are (different) methods to lift funds,” he mentioned, emphasizing the transfer away from conventional company valuations. “If you wish to innovate, it is a critical journey. There are financing choices obtainable and there are other ways to get there,” he mentioned, noting that there isn’t any one various mannequin and every firm should discover its personal path. One of many components driving the innovation course of from India is that many main international firms have arrange store in India, thereby contributing to the strengthening of the ecosystem.
Prasad additionally emphasised that the home housing market will turn out to be engaging for innovators.
Responding to a query throughout a panel dialogue, Shreehas Tambe, MD and CEO of Biocon Biologics, mentioned it was time for the Indian pharmaceutical trade to maneuver up the worth chain. He mentioned the trick is to do it in a fiscally accountable approach, and that it is nonetheless federal funding that provides some huge cash to foster innovation in america. There are limits to what the personal sector can do, he added.
Eric Mansion, Sanofi’s basic supervisor for India and Southeast Asia, mentioned the shift from a concentrate on amount to a concentrate on worth will rely on the pace of implementation and authorities intervention via coverage assist and initiatives.
Winslow Thakkar, president and basic supervisor of Lilly India, mentioned India has the potential to emerge as a medical trial hub. Stefan Miltenyi, founder and president of Miltenyi Biotec, talked about analysis funding in Europe and the way it helped slender the concentrate on innovation.
